Servier’s targeted brain tumour therapy approved in EU
The European Commission has approved pharmaceutical company Servier’s Voranigo therapy for patients with a specific type of brain tumour. Voranigo has now been approved for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation… Read More
